Amendment and Response dated February 16, 2010 Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 4

Amendments to the Claims:

This claim listing replaces all prior versions, and listings of claims in the application.

Please amend the claims as follows:

1-39. (Previously cancelled)


40. (Currently amended) Compounds A compound of the general formula



wherein the template is selected from the group consisting of ^DPro-^LPro and ^LPro-^DPro;



is a group of one of the formulae



Amendment and Response dated February 16, 2010 Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 5

_

is a group of one of the formulae

A82 A83

B. CO. is Asn; Cys; Gln; His; Met; Phe; Pre; Ser; Thr; Trp; Tyr; Sar; 4AmPhe; 3AmPhe; 2AmPhe; Phe(mC(NH₃)=NH); Phe(pC(NH₃)=NH); Phe(mNHC (NH₂)=NH); Phe(pNHC (NH₃)=NH); Phe; Cha; C₄al; C₅al; 2-Nal; 1-Nal; 4Cl-Phe; 3Cl-Phe; 2Cl-Phe; 3,4Cl₂Phe; 4F-Phe; 3F-Phe; 2F-Phe; Tic; Thi; Tze; Mso; Y(Bzl); Bip; S(Bzl); T(Bzl); hCha; hCys; hSer; hPhe; Bpa;

Application No.: 10/550,778

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 6

Pip: OctG; MePhe: MeNle; MeAla; Melle; MeVal; or MeLeu; or B is a group, having (L)-configuration, of formula

wherein R²⁰ is H; or lower alkyl; and R⁶⁴ is alkyl; alkenyl; aryl; aryl lower alkyl; or heteroaryllower alkyl;

R+ is hydrogen or lower alkyl;

R² is H; lower alkyl; lower alkenyl; (CH₂)_mOR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkenyl); (CH₂)_mSR⁵⁶ (where R⁵⁶ is lower alkyl; or R³² and R³⁴ taken together are (CH₂)₂ 6; (CH₂)₂ (CH₂)₃ 6;

-(CH₂)₂S(CH₂)₂; or (CH₂)₂PR⁵²(CH₂)₂; where R⁵² is H; or lower alky!); -(CH₂)₂OCONR³³R³⁶ (where R³³ is H; lower alky!; or lower alkeny!; R²³ is lower alky!; or R³³ and R²⁵ taken together are

 $(CH_2)_{26}$; $(CH_2)_3O(CH_3)_3$; $(CH_3)_3S(CH_2)_3$; or $(CH_3)_2NR^{47}(CH_3)_3$; where R^{47} is H; or lower alkel+:

 $-(CH_2)_m NR^{26}CONR^{33}R^{82}$ (where R^{20} is H; or lower alkyl; R^{33} is H; or lower alkyl; or lower alkyl; or lower alkyl; or R^{23} and R^{82} taken together are $-(CH_2)_{24}$; $-(CH_2)_{24}$; $-(CH_2)_{24}$; $-(CH_2)_{24}$; $-(CH_2)_{24}$; $-(CH_2)_{24}$; where R^{57} is H; or lower alkyl); $-(CH_2)_{24}$; $-(CH_2)_{24}$; where R^{57} is H; or lower alkyl); $-(CH_2)_{24}$; $-(CH_2)_{24}$; where $-(CH_2)_{24}$; $-(CH_2$

(CH₂)₆N(R²⁰)COR⁵⁴(where: R⁵⁰ is H; or lower alkyl; R⁵⁴ is lower alkyl; or lower alkenyl); (CH₂)₆CONR⁵⁵(where R⁵⁵ is lower alkyl; or lower alkenyl); (CH₂)₆CONR⁵⁸R⁵⁶(where R⁵⁸-is lower alkyl; or lower alkyl; or lower alkyl; or R⁵⁸ and R⁶⁵ taken together are-(CH₂)₂₋₆; (CH₂)₂₋₆; (CH₂)₂₋₇

-(CH₂)₂NR⁵⁷(CH₂)₂; where R⁵⁷ is H; or lower alkyl); (CH₂), PO(OR⁶⁰)₂ (where R⁶⁰ is lower

alkyl; or lower alkenyl); (CH₂)₂SO₂R⁵³ (where R⁶³ is lower alkyl; or lower alkenyl); or (CH₂)₃C₆H₄R⁸ (where R⁸ is H; F; Cl; Cl₂; lower alkyl; lower alkenyl; or lower alkenyl); or lower alkenyl; or lower alkenyl); (CH₂)₃C₆R⁵³ (where R⁵⁶ is lower alkyl; or lower alkenyl); (CH₂)₃C₆R⁵³ (where R⁵⁶ is lower alkyl; or lower alkenyl); (CH₂)₃C₆R⁵³ (where R⁵⁶ is H; or lower alkyl; or R⁵³ and R⁵⁴ taken together are (CH₂)₂₊; (CH₂)₂₊(CH₂)₂₊; (CH₂)₂₊(CH₂)₂₊; (CH₂)₂₊; where R⁵³ is H; or lower alkyl; or R⁵³ and R⁵⁶ (where R⁵³ is H; or lower alkyl; or R⁵³ and R⁵⁶ (cH₂)₂₋; (CH₂)₂C₆C(H₂)₂₋; (CH₂)₂C(CH₂)₂₋; (CH₂)₂C(CH₂C(CH₂)₂C(CH₂C(CH₂)₂C(CH₂C(CH₂C(CH₂C(CH₂C(CH₂C(CH

(CH₂)₂O(CH₂)₂; (CH₂)₂S(CH₂)₂; or (CH₂)₂PR^{E2}(CH₂)₂; where R^{S2} is H; or lower alkyH; (CH₂)₂N(R²⁰)COR^{E4} (where R²⁰ is H; or lower alkyH; R^{E4} is lower alkyH; or R^{S4} and R^{S9} (where R^{S4} is lower alkyH; or lower alkyH; or lower alkyH; or R^{S4} and R^{S9} (aken together are—(CH₂)₂D₂COR^{S4}

- $(CH_2)_2O(CH_2)_2$ -; $(CH_2)_2S(CH_2)_2$; or $(CH_2)_2S(CH_2)_2$; where R^{62} is H; or lower alkyl); $(CH_2)_2FO(OR^{66})_2$ (where R^{62} is lower alkyl; or lower alkyl; $(CH_2)_2FO(DR^{62})_2$ (where R^{62} is lower alkyl; or lower alkoyl); or $(CH_2)_2G_2R^{62}$ (where R^{61} is H; F; CH; CF_3 ; lower alkyl; lower alkonyl; or lower alkoy);

R⁴ is H; lower alkyl; lower alkenyl; (CH₂)_mOR³⁵ (where R⁵⁶ is lower alkyl; or lower alkenyl); (CH₂)_mSR⁵⁶ (where R⁵⁶ is lower alkyl; or lower alkenyl); (CH₂)_mNR³³R³⁶ (where R³⁵ is lower alkyl; or lower alkenyl; R³⁴ is H; or lower alkyl; or R³³ and R²⁴ taken together are (CH₂)₂,6-7 (CH₂)₂,2-(CH₂)₂; (CH₂)₂; (CH₂)₂; (CH₂)₃; or (CH₂)₂,2(CH₂)₂; where R⁶² is H; or lower alkyl; or R³³ and R³⁴ taken together are (CH₂)₂,2-(CH₂)₂,2-(CH₂)₂; (CH₂)₂,2-(CH₂)₂; or (CH₂)₂,2-(CH₂)₂; (CH₂)₂; or (CH₂)₂,2-(CH₂)₂; where R⁵³ is H; or lower alkyl; (CH₂)₃, NR³⁰CONR³³R³² (where R³⁰ is H; or lower alkyl; R³³ is H; or lower alkyl; or lower al

```
Application No.: 10/550,778
Amendment and Response dated February 16, 2010
Reply to Office Action of October 14, 2009
Docket No.: 753-54 PCT/US
Page 8
```

(CH2)24+

(CH₂)₂O(CH₂)₂; (CH₂)₂S(CH₂)₂; or (CH₂)₂NR⁵²(CH₂)₂; where R⁵² is H; or lower alkyH; (CH₂)_mN(R³⁰)COR⁵⁴ (where ·R²⁰ is H; or lower alkyH; R⁶⁴ is lower alkyH; or lower al

 $(CH_2)_2O(CH_2)_2$; $(CH_2)_2S(CH_2)_2$; or $(CH_2)_2kRE^{22}(CH_2)_2$; where R^{22} ; is:H; or lower alkyl); $(CH_2)_nPO(OR^{62})_2$ (where R^{62} is lower alkyl; or lower alkenyl); $(CH_2)_nPO(CR^{62})_2$ (where R^{62} is lower alkyl; or lower alkenyl); or $(CH_2)_nC_6H_4R^{8}$ (where R^{8} is H; F; Cl; CF_3 ; lower alkyl; lower alkenyl; or lower alkenyl; or lower alkyl; lower alkenyl; or lower alkenyl; or $(CH_2)_nC_6H_4R^{8}$.

R⁵ is lower alkyl; lower alkenyl; (CH₃)₂OR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkenyl); (CH₂)₂SR⁵⁶ (where R⁵⁶ is lower alkyl; or lower alkenyl); (CH₂)₂SR⁵⁸ (where R⁵⁸ is lower alkyl; or lower alkenyl); R⁵⁴ is H; or lower alkyl; or R⁵³ and R⁵⁴ taken together are (CH₂)₂s₅; (CH₃)₂O(CH₃)₂;

-(CH₂)₂S(CH₂)₂; or (CH₂)₂NR⁵²(CH₂)₂; where R⁵² is H; or lower alkyl; (CH₂)₂OCONR³³R³⁶ (where R³³ is H; or lower alkyl; or lower alkenyl; R⁷⁵ is lower alkyl; or R³³ and R³⁵ taken together are

-(CH₂)₂₄+; (CH₂)₂O(CH₂)₂+; (CH₂)₂S(CH₂)₂+; or -(CH₂)₂NR²²(CH₃)₂+; where R³² is H; or lower alkyl; R³³ is H; or lower alkyl; R³³ is H; or lower alkyl; R³⁴ is H; or lower alkyl; or lower alkyl; or R³² and R⁴³ taken together are -(CH₂)_{2.6}+; (CH₂)_{2.0}+; (CH₂)_{2.6}+;

-(CH₂)₂S(CH₂)₂; or (CH₂)₂NR⁵⁷(CH₂)₂; where R⁵² is H; or lower alkyl); (CH₂)₈N(R³⁰)COR⁶⁴ (where: R³⁰ is H; or lower alkyl; or heteroaryl lower alkyl); (CH₂)₈COOR⁵⁵ (where alkyl); (CH₂)₈COOR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkyl; or CH₂)₈CONR⁵⁸R⁵⁰ (where R⁵⁵ is lower alkyl; or lower alkyl; or R⁵⁵ and R⁵⁰ taken together are -(CH₂)₂CH₂)₂; (CH₂)₂: (CH₂)₂C(CH₂)₂; (CH₂)₂; where R⁵⁷ is H; or lower alkyl;

-(CH₂)₀PO(OR⁶⁰)₂ (where R⁶⁰ is lower alkyl; or lower alkenyl); (CH₂)₀SO₂R⁶² (where R⁶² is

lower alkyl; or lower alkenyl); or $-(CH_2)_4C_6H_4R^8$ (where R^8 is H_1F_1 ; CI_1 ; CF_3 ; lower alkyl; lower alkenyl; or lower alkenyl; or lower alkenyl; or lower alkenyl;

R⁶ is H; lower alkyl; lower alkenyl; (CH₂)₆OR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkenyl); (CH₂)₆SR⁵⁶ (where R⁵⁶ is lower alkyl; or lower alkenyl); (CH₂)₆SR⁵⁸ (where R⁵⁶ is lower alkyl; or lower alkenyl; R⁵⁴ is H; or lower alkyl; or R⁵³ and R⁵⁴ taken together are (CH₂)₂6+-(CH₂)₂0(CH₂)₃-1

-(CH₂)₂S(CH₂)₂; or (CH₂)₂NR²⁷(CH₂)₂; where R⁵⁷ is H; or lower alkyl); (CH₂)₂OCONR²³ R²⁶ (where R²³ is H; or lower alkyl; or lower alkenyl; R²⁵ is lower alkyl; or R²³ and R²⁵ taken together are

(CH₂)_{2.6} + (CH₂)₂O(CH₃)₂ + (CH₃)₂S(CH₃)₂ + or (CH₃)₂NR²³(CH₃)₃ + where R²³ is H; or lower alkyl; R²³ is H; or lower alkyl; or lower alkyl; R²³ is H; or lower alkyl; or lower alkyl; or lower alkyl; R²³ is H; or lower alkyl; or R²³ and R²³ taken together are (CH₃)_{2.6} + (CH₃)_{2.6} (CH₃)_{3.6} (CH₃)_{3.6}

(CH₂)₂S(CH₂)₂·or (CH₂)₂NR²³(CH₂)₃·where R²⁷ is H; or lower alkyl); (CH₂)₆N(R²⁰)COR⁶⁴ (where R²⁰ is H; or lower alkyl; R²⁴ is lower alkyl; or lower alkyl; occur alkyl; or lower alkyl; or (CH₂)₂CONR⁶⁴R⁵⁰, (where R⁶⁴ is lower alkyl; or lower alkyl; or R⁶⁴ and R⁶⁹ taken together are (CH₂)₂Co(CH₂)₂·· (CH₂)₂CO(CH₂)₃·· (CH₂)₂CO(CH₂)₃·· (CH₂)₂CO(CH₂)₃·· (CH₂)₃CO(CH₂)₃·· (CH₂)₃·· (CH₂)₃CO(CH₂)₃·· (CH₂)₃CO(CH₂)₃·· (CH₂)₃·· (CH₂)₃CO(CH₂)₃·· (CH₂)₃·· (CH

(CH₂)₂NR⁵²(CH₂)₂; where R⁵² is H; or lower alkyl; (CH₂)₈PO(OR⁶⁰)₂ (where R⁵⁰ is lower alkyl; or lower alkenyl); (CH₂)₈SO₂R⁶² (where R⁶² is lower alkyl; or lower alkenyl); or (CH₂)₈CH₄R⁸ (where R⁸ is H; F; Cl; CF₃; lower alkyl; lower alkenyl; or lower alkenyl; R² is lower alkyl; lower alkenyl; (CH₂)₈OR⁶⁵ (where R⁶⁵ is lower alkyl; or lower alkenyl); (CH₂)₈SR⁵⁶ (where R⁵⁶ is lower alkyl; or lower al

(CH₂)₂S(CH₂)₂; or (CH₂)₂NR⁵⁷(CH₂)₂; where R⁵² is H; or lower alkyl); (CH₂)₄OCONR³³R³⁶ (where R³³ is H; or lower alkyl; or lower alkenyl; R³³ is lower alkyl; or R³³ and R³³ taken together are

Amendment and Response dated February 16, 2010 Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 10

(CH₂)_{2.6}: (CH₂)₂O(CH₂)₂: (CH₃)₂S(CH₂)₂: or (CH₂)₂NR²²(CH₂)₂: where R²² is H; or lower alkyl; (CH₂)₂O(CH₂)₂: (CH₂)₂S(CH₂)₂: or (CH₂)₂NR²²(CH₂)₃: where R²² is H; or lower alkyl; (CH₂)₃OONR²³(R²⁶) (where R²⁵ is lower alkyl; or lower alkyl; or lower alkyl; or lower alkyl; and R²⁶ is H; or lower alkyl; or R²⁶ and R²⁶ taken together are (CH₂)₂CH₂O(CH₂)₂ (CH₂)₂C(CH₂)₂: or (CH₂)₂O(CH₂)₂ (CH₂)₂C(CH₂)₂: or (CH₂)₂C(CH₂)₂C(CH₂)₂C(CH₂)₂: or alkyl; or lower alkyl); or lower alkyl; or lower alkyl; or lower alkyl; or lower alkyl; or lower alkoyl); or (CH₂)₂C(

(CH₂)₂O(CH₂)₂· (CH₂)₂S(CH₂)₂· or (CH₂)₂NR²³(CH₃)₂· where R²³ is H; or lower alkyl); (CH₂)₂OCONR²³R²⁵ (where R²³ is H; or lower alkyl; or R²³ and R²⁵ (aken together are (CH₃)₂A₇· (CH₂)₂O(CH₃)₂· (CH₂)₃S(CH₃)₂· or (CH₂)₂NR²³(CH₂)₂· where R²³ is H; or lower alkyl); (CH₃)₃NR²³CONR²³R²³ (where R²³ is H; or lower alkyl; or lowe

(CH₂)₂O(CH₂)₂ + (CH₂)₂S(CH₂)₂ + or (CH₂)₂NRS⁵²(CH₂)₂ ; where R⁵² is H; or lower alkyl); (CH₂)₆N(R⁵⁰)COR⁶⁴ (where R⁵² is H; or lower alkyl; R⁶⁴ is lower alkyl; or lowe

(CH₂)₂O(CH₂)₂· (CH₂)₂S(CH₂)₂· or -(CH₂)₂NR²¹(CH₂)₂· where R²¹ is H; or lower alkyl); (CH₂)₆PO(OR²⁶); (where R²⁶ is lower alkyl; or lower alkenyl); (CH₂)₆SO₂R²⁶ (where R²⁶ is

Page 11

lower alkyl; or lower alkenyl); or $-(CH_2)_qC_6H_4R^8$ (where R^8 is H_1 ; F_1 ; CI_1 ; CF_3 ; lower alkyl; lower alkenyl; or lower alkeny);

R¹¹ is H; lower alkyl; lower alkenyl; (CH₂)_mQR⁵⁵ (where R⁵⁵ is lower alkyl; or lower alkenyl); (CH₂)_mNR⁵⁶ (where R⁵⁶ is lower alkyl; or lower alkyl; or R⁵³ and R⁵⁴ taken together are (CH₂)₂₋₆; alkyl; or lower alkyl; or R⁵³ and R⁵⁴ taken together are (CH₂)₂₋₆; (CH₂)₂₋₆(CH₂)₂₋₇; (CH₂)₂₋₇(CH₂)₂₋₇; (CH₂)₂₋₇(CH₂)₂₋₇; (CH₂)₂₋₇(CH₂)₂₋₇; (CH₂)₂₋₇(CH₂)₂₋₇; (CH₂)₂₋₇; where R⁵³ is H; or lower alkyl; or R⁵³ and R⁵³ taken together ar (CH₂)₂₋₇; (CH₂)₂₋₇(CH₂)₂₋₇; (CH₂)₂₋₇; (CH₂

-(CH₂)₂O(CH₂)₂+ -(CH₂)₂S(CH₂)₂+ or -(CH₂)₂R(SH₂)₂-; where R⁵² is H; or lower alkyH; -(CH₂)_mN(R²⁶)COR⁶⁴ (where R²⁰ is H, or lower alkyH; R⁶⁴ is lower alkyH; or lower alkyH; or lower alkyH; or CH₂)_mCONR³⁸ (where R³² is lower alkyH; or lower alkyH; or R⁵⁴ and R⁵⁵ (where R⁵⁶ is lower alkyH; or lower alkyH; or R⁵⁶ and R⁵⁵ taken together are—(CH₂)₂CONR³⁸ (CH₂)₂CONR³⁸ (CH₂)₂CONR³⁸ (CH₂)₃CONR³⁸ (CH₂)₃CONR³⁸

-(CH₂)₂O(CH₂)₂+-(CH₂)₂S(CH₂)₂·or (CH₂)₂PlR⁵²(CH₂)₂·, where R^{52} is H; or lower alkyl); -(CH₂)₂PO(OR⁵⁰)₂ (where R^{50} is lower alkyl; or lower alkenyl); (CH₂)₂SO₂ R^{62} (where R^{62} is lower alkyl; or lower alkenyl; or (CH₂)₃C₆H₄ R^{6} (where R^{6} is H; F; CI; CF₂; lower alkyl; lower alkenyl; or lower alkoxy);

R¹² is H; lower alkyl; lower alkenyl; (CH₂)_mQR⁵⁵ (where R¹⁵ is lower alkyl; or lower alkenyl); (CH₂)_mSR⁵⁶ (where R²⁶ is lower alkyl; or lower alkyl; or R²⁷ and R²⁴ taken together are (CH₂)₂₊; (CH₂)

Page 12

(CH2)2-6-;

(CH₂)₂O(CH₂)₂; (CH₂)₂S(CH₂)₂; or (CH₂)₂RR⁵²(CH₂)₂; where R⁵² is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl); (CH₂)_mN(R³⁶)COR⁶⁵ (where R⁵² is lower alkyl; or lower alkyl;

 $(CH_2)_2O(CH_2)_2$; $(CH_2)_2S(CH_2)_2$; or $(CH_2)_2NRS^{22}(CH_2)_2$; where R^{22} is H; or lower alkyl); $(CH_2)_2O(CH_2)_$

R20 is H: or lower alkyl;

 $R^{25}_{i5}H_{i} \text{ lower alkyl; lower alkenyl; } (CH_{2})_{m}QR^{55}_{i} \text{ (where R^{55}_{i5} lower alkyl; or lower alkenyl); } (CH_{2})_{m}NR^{32}R^{34}_{i5} \text{ (where R^{34}_{i5} lower alkyl; or R^{34}_{i5}$ and R^{35}_{i5} (where R^{33}_{i5} H; or lower alkyl; or R^{34}_{i5}$ and R^{35}_{i5} (where R^{33}_{i5} H; or lower alkyl; or R^{34}_{i5}$ and R^{35}_{i5} (where R^{34}_{i5} h; or lower alkyl; or R^{34}_{i5}$ and R^{35}_{i5} (where R^{34}_{i5} h; or lower alkyl; or R^{34}_{i5}$ and R^{35}_{i5} (where R^{34}_{i5} h; or lower alkyl; or R^{35}_{i5}$ (CH_{2})_{2}C(CH_$

(CH₂)₂NR⁵⁷(CH₂)₂, where R⁵⁷ is H; or lower alkyl); (CH₂)_mNR²⁰CONR³³ R⁵⁸ (where R³⁰ is H; or lower alkyl; R³³ and R⁵² taken together are (CH₂)₂6; (CH₂)₂(CH₂)₂; (CH₃)₂S(CH₃)₂; or (CH₂)₂NR⁵⁷(CH₂)₂; where R⁵⁷ is H; or lower alkyl); (CH₂)_mN(R²⁰)COR⁶⁴ (where: R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkyl; CH₂)₂COOR⁵² (where R⁵² is lower alkyl; or lower alkyl; or R⁵⁴ is lower alkyl; or lower alkyl; or R⁵⁵ (CH₂)₂CONR⁵⁸ R⁵⁹ (where R⁵⁵ is lower alkyl; or lower alkyl; or R⁵⁶ and R⁵⁹ taken together are (CH₂)₂6; (CH₂)₂O(CH₂)₂; (CH₂)₂COCH₂)₂; or (CH₂)₂NR⁵⁷(CH₂)₂; where R⁵⁷ is H; or lower alkyl; or R⁵⁶ (CH₂)₂; where R⁵⁷ is H; or lower alkyl;

 $(CH_2)_n PO(OR^{4n})_2$ (where R^{4n} is lower alkyl; or lower alkenyl). $(CH_2)_n SO_2 R^{4n}$ (where R^{4n} is lower alkyl; or lower alkenyl); or $(CH_2)_n C_6 H_4 R^8$ (where R^8 is H; F; CI; CF_3 ; lower alkyl; lower alkenyl; or lower alkoxy);

```
Application No.: 10/550,778
Amendment and Response dated February 16, 2010
Reply to Office Action of October 14, 2009
Docket No.: 753-54 PCT/US
```

Page 13

R26 is H; lower alkyl; lower alkenyl; -(CH2)...OR55 (where R55 is lower alkyl; or lower alkenyl); (CH₂), NR³³R³⁴ (where R³³ is lower alkyl; or lower alkenyl; R³⁴ is H; or lower alkyl; or R²³ and R34 taken together are (CH2)26; (CH2)2O(CH2)2; (CH2)2S(CH2)2; or (CH2)2NR55(CH2)2; where R52 is H; or lower alkyl): (CH-)...OCONR32R35 (where R32 is H; or lower alkyl): or lower alkenyl: R35 is lower alkyl: or R35 and R75 taken together are (CH2)26: (CH2)26: (CH2)2S(CH2)2-: or -(CH₂)₂NR⁵⁷(CH₂)₂: where R⁵⁷ is H: or lower alkyl): (CH₂)₂NR⁵⁰CONR⁵³R⁸² (where R⁵⁰ is H; or lower alkyl; R33 is H; or lower alkyl; or lower alkenyl; R82 is H; or lower alkyl; or R33 and R82 taken together are (CH₂)₂₋₆; (CH₂)₂O(CH₂)₂; (CH₂)₂S(CH₂)₂; or (CH₂)₂NR⁵⁷(CH₂)₂; where R⁵⁷ is H; or lower alkyl); (CH₂), N(R²⁰)COR⁶⁴ (where: R²⁰ is H; or lower alkyl; R⁶⁴ is lower alkyl; or lower alkenyl); (CH2)aCOOR 52 (where R52 is lower alkyl; or lower alkenyl); (CH₂)_aCONR⁵⁸R⁵⁹ (where R⁵⁸ is lower alkyl; or lower alkenyl; and R⁵⁰ is H; lower alkyl; or R⁵⁸ and R⁵⁹ taken together are (CH₂)₂₆+; (CH₂)₂O(CH₂)₂+; (CH₃)₂S(CH₃)₂+or (CH₂)₂NR⁵⁷(CH₂)₂where R57 is H; or lower alkyl); -(CH₂)_oPO(OR⁶⁰)₂ (where R⁶² is lower alkyl; or lower alkenyl); (CH₂)_oSO₂R⁶² (where R⁶² is lower alkyl; or lower alkenyl); or -(CH2), C6H4R8 (where R8 is H; F; Cl; CF3; lower alkyl; lower alkenyl; or lower alkoxy); or, alternatively, R25 and R26 taken together are (CH2)2.4: (CH₂);O(CH₂);-: -(CH₂)₂S(CH₂)₂ ; or (CH₂)₂NR³⁴(CH₂)₂-: R33 is H; alkyl, alkenyl; (CH2) (CH2 $-(CH_2)_m(CHR^{61})_kOCONR^{75}R^{82}; -(CH_2)_m(CHR^{61})_kNR^{20}CONR^{78}R^{83};$ (CH₂)₆(CHR⁶¹)₅COR⁶⁴; (CH₂)₆(CHR⁶¹)₆-CONR⁶⁸R⁵⁹; (CH₂)₆(CHR⁶¹)₆PO(OR⁶⁹)₅₄; -(CH2)a(CHR6+)a-SO2R62; or (CH2)a(CHR6+)aC6H4R8; R24 is H: lower alkyl; aryl, or aryl-lower alkyl; R34 and R34 taken together can form: (CH2)26; (CH2)2O(CH2)2; (CH2)2S(CH2)2; or ———(CH₂½NR⁵⁷(CH₂½-: R 50 is H: lower alkyl; or aryl-lower alkyl; R⁵⁷ is H; lower alkyl; lower alkenyl; aryl lower alkyl; or heteroaryl lower alkyl;

```
Application No.: 10/550,778
Amendment and Response dated February 16, 2010
Reply to Office Action of October 14, 2009
Docket No.: 753-54 PCT/US
Page 14
R58 is H: lower alkyl; lower alkenyl; aryl; heteroaryl; aryl lower alkyl; or heteroaryl-lower
alkyl:
R59 is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower
alkyl; or
R58 and R59 taken together can form: (CH2)26; (CH2)2O(CH2)2; (CH2)2S(CH2)2; or
—— (CH₂)₂NR<sup>57</sup>(CH₂)₂-;
R60 is H: lower alkyl: lower alkenyl; aryl; or aryl-lower alkyl;
R<sup>64</sup> is alkyl; alkenyl; aryl; heteroaryl; aryl lower alkyl; heteroaryl lower alkyl; (CH<sub>2</sub>), OR<sup>55</sup>;
 -----(CH2)_mNR33R34:-(CH2)_mOCONR35R82:-(CH2)_mNR30CONR38R82:-(CH2)_COOR37;
         -(CH-)_NR58R59; or -(CH2)_PO(COR69)2;
 R<sup>62</sup> is lower alkyl; lower alkenyl; aryl, heteroaryl; or aryl lower alkyl;
 R64 is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl lower alkyl; heteroaryl-lower alkyl;
 (CH<sub>2</sub>)<sub>6</sub>(CHR<sup>64</sup>)<sub>5</sub>OR<sup>65</sup>; (CH<sub>2</sub>)<sub>6</sub>(CHR<sup>64</sup>)<sub>5</sub>SR<sup>66</sup>; or (CH<sub>2</sub>)<sub>6</sub>(CHR<sup>64</sup>)<sub>5</sub>NR<sup>34</sup>R<sup>63</sup>;
 +(CH2)p(CHR61),+OCONR75R82;-(CH2)p(CHR61),,NR20CONR78R82;
 Z and Z^1 are chains of n and, respectively, n' \alpha-amino acid residues whereby either n is 4 and n'
 is 6 or n is 5 and n' is 7, the positions of said amino acid residues in said chain Z being counted
 starting from the N-terminal amino acid and the positions of said amino acid residues in eaid
 chain Z1 being counted starting from the C-terminal amino acid, whereby these amino acid
 residues are, depending on their position in the chains, Gly, or Pro, or of one of the types
```

```
C: NR<sup>30</sup>CH(R<sup>32</sup>)CO;
D: NR<sup>30</sup>CH(R<sup>32</sup>)CO;
E: NR<sup>30</sup>CH(R<sup>32</sup>)CO;
F: NR<sup>30</sup>CH(R<sup>34</sup>)CO; and
H: NR<sup>30</sup>CH(CO) (CH<sub>2</sub>)<sub>4.7</sub>-CH(CO) NR<sup>30</sup>;
NR<sup>30</sup>CH(CO) (CH<sub>2</sub>)<sub>p</sub>SS(CH<sub>2</sub>)<sub>p</sub>-CH(CO) NR<sup>30</sup>;
NR<sup>30</sup>CH(CO) (CH<sub>2</sub>)<sub>p</sub>NR<sup>30</sup>CO(CH<sub>2</sub>)<sub>p</sub>-CH(CO) NR<sup>30</sup>; and
```

```
Application No.: 10/550,778
Amendment and Response dated February 16, 2010
Reply to Office Action of October 14, 2009
Docket No.: 753-54 PCT/US
Page 15
Ŀ___NR86CH₂CO÷
R<sup>22</sup> is H, lower alkyl; lower alkenyl; (CH<sub>2</sub>),(CHR<sup>61</sup>),OR<sup>85</sup>; or (CH<sub>2</sub>),(CHR<sup>61</sup>),SR<sup>85</sup>;
R<sup>73</sup> is (CH<sub>2</sub>)<sub>0</sub>R<sup>27</sup>; (CH<sub>2</sub>)<sub>0</sub>O(CH<sub>2</sub>)<sub>0</sub>R<sup>27</sup>; (CH<sub>2</sub>)<sub>0</sub>S(CH<sub>2</sub>)<sub>0</sub>R<sup>23</sup>; or (CH<sub>2</sub>)<sub>0</sub>NR<sup>20</sup>(CH<sub>2</sub>)<sub>0</sub>R<sup>23</sup>;
R<sup>74</sup>-is--(CH<sub>2</sub>)<sub>0</sub>NR<sup>78</sup>R<sup>79</sup>;-(CH<sub>2</sub>)<sub>0</sub>NR<sup>77</sup>R<sup>80</sup>;-(CH<sub>2</sub>)<sub>0</sub>C(=NR<sup>80</sup>)NR<sup>78</sup>R<sup>79</sup>;-
----(CH<sub>2</sub>)<sub>6</sub>C(=NOR<sup>50</sup>)NR<sup>78</sup>R<sup>70</sup>:
____(CH<sub>2</sub>),C(=NNR<sup>78</sup>R<sup>70</sup>)NR<sup>78</sup>R<sup>70</sup>; (CH<sub>2</sub>),NR<sup>80</sup>C(=NR<sup>80</sup>)NR<sup>78</sup>R<sup>70</sup>;
 (CH<sub>2</sub>)<sub>n</sub>N=C(NR<sup>78</sup>R<sup>80</sup>)NR<sup>73</sup>R<sup>80</sup>: (CH<sub>2</sub>)<sub>n</sub>C<sub>6</sub>H<sub>4</sub>NR<sup>78</sup>R<sup>79</sup>; (CH<sub>2</sub>)<sub>n</sub>C<sub>6</sub>H<sub>4</sub>NR<sup>77</sup>R<sup>80</sup>;
              -(CH_2)_aC_aH_4C(=NR^{80})NR^{28}R^{29}; -(CH_2)_aC_aH_4C(=NOR^{50})NR^{28}R^{29};
 ------(CH<sub>2</sub>),C<sub>6</sub>H<sub>4</sub>C(=NNR<sup>78</sup>R<sup>79</sup>)NR<sup>78</sup>R<sup>79</sup>;--(CH<sub>2</sub>),C<sub>6</sub>H<sub>4</sub>NR<sup>80</sup>C(=NR<sup>80</sup>)NR<sup>78</sup>R<sup>79</sup>;
 -----(CH<sub>2</sub>),<sub>6</sub>C<sub>6</sub>H<sub>4</sub>N=C(NR<sup>78</sup>R<sup>60</sup>)NR<sup>79</sup>R<sup>50</sup>; (CH<sub>2</sub>),O(CH<sub>2</sub>),NR<sup>78</sup>R<sup>20</sup>; (CH<sub>2</sub>),O(CH<sub>2</sub>),NR<sup>77</sup>R<sup>50</sup>;
              <del>__(CH_),O(CH2),C(=NR<sup>80</sup>)NR<sup>78</sup>R<sup>79</sup>;_(CH2),O(CH2),C(=NOR<sup>60</sup>)NR<sup>78</sup>R<sup>79</sup>;</del>
 -----(CH2),O(CH2),C(=NNR<sup>28</sup>R<sup>29</sup>)NR<sup>28</sup>R<sup>29</sup>; (CH2),O(CH2),NR<sup>80</sup>C(=NR<sup>80</sup>)NR<sup>28</sup>R<sup>29</sup>;
              -(CH-),O(CH-),,N=C(NR<sup>28</sup>R<sup>80</sup>1NR<sup>29</sup>R<sup>80</sup>;-(CH-),O(CH-),,C<sub>K</sub>H<sub>4</sub>CNR<sup>28</sup>R<sup>29</sup>;
  -----(CH<sub>2</sub>),O(CH<sub>2</sub>),C<sub>6</sub>H<sub>4</sub>C(-NR<sup>80</sup>)NR<sup>28</sup>R<sup>29</sup>; (CH<sub>2</sub>),O(CH<sub>2</sub>),C<sub>6</sub>H<sub>4</sub>C(-NOR<sup>50</sup>)NR<sup>28</sup>R<sup>29</sup>;
  (CH<sub>2</sub>),O(CH<sub>2</sub>),C<sub>6</sub>H<sub>4</sub>C(=NNR<sup>28</sup>R<sup>29</sup>)NR<sup>28</sup>R<sup>29</sup>:
             -(CH_2)_*O(CH_2)_*C_6H_4NR^{80}C(=NR^{80})NR^{78}R^{79}; -(CH_2)_*S(CH_2)_*NR^{78}R^{79};
  -----(CH2),S(CH2),,NR<sup>27</sup>R<sup>80</sup>; (CH2),S(CH2),C(=NR<sup>80</sup>)NR<sup>78</sup>R<sup>79</sup>;
  _____(CH<sub>2</sub>)<sub>8</sub>S(CH<sub>2</sub>)<sub>8</sub>C(=NOR<sup>50</sup>)NR<sup>78</sup>R<sup>79</sup>; (CH<sub>2</sub>)<sub>8</sub>(CH<sub>2</sub>)<sub>8</sub>C(=NNR<sup>78</sup>R<sup>79</sup>)NR<sup>78</sup>R<sup>79</sup>;
  -----(CH<sub>2</sub>),S(CH<sub>2</sub>),MR<sup>80</sup>C(-NR<sup>80</sup>)NR<sup>38</sup>R<sup>39</sup>; (CH<sub>2</sub>),S(CH<sub>2</sub>),M-C(NR<sup>38</sup>R<sup>80</sup>)NR<sup>39</sup>R<sup>80</sup>;
      (CH_2)_8C(CH_2)_9C_6H_4CNR^{78}R^{79}; (CH_2)_8C(CH_2)_9C_6H_4C(-NR^{89})NR^{78}R^{79};
        <del>~~~~(CH2),S(CH2),G6H4C(=NOR<sup>50</sup>)NR<sup>38</sup>R<sup>39</sup>;~(CH2),S(CH2),G6H4C(=NNR<sup>38</sup>R<sup>39</sup>)NR<sup>38</sup>R<sup>39</sup>;</del>
   ------(CH<sub>2</sub>)<sub>8</sub>S(CH<sub>2</sub>)<sub>8</sub>C<sub>6</sub>H<sub>4</sub>NR<sup>80</sup>C(-NR<sup>80</sup>)NR<sup>38</sup>R<sup>39</sup>;-(CH<sub>2</sub>)<sub>8</sub>NR<sup>80</sup>COR<sup>64</sup>;-(CH<sub>2</sub>)<sub>8</sub>NR<sup>80</sup>COR<sup>54</sup>;
   ———(CH₂)<sub>n</sub>NR<sup>80</sup>CONR<sup>78</sup>R<sup>70</sup>; or (CH₂)<sub>n</sub>C<sub>6</sub>H<sub>4</sub>NR<sup>80</sup>CONR<sup>78</sup>R<sup>70</sup>;
   R75 is lower alkyl; lower alkenyl; or aryl lower alkyl;
   R23 and R25 taken together can form: (CH2)2-6; (CH2)2O(CH2)2; (CH2)2S(CH2)2; or
           (CH<sub>2</sub>)<sub>2</sub>NR<sup>52</sup>(CH<sub>2</sub>)<sub>2</sub>-;
   R25 and R62 taken together can form: (CH2)26; (CH2)2O(CH2)2; (CH2)2S(CH2)2; or
```

(CH-)NR⁵⁷(CH-)-

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 16

R²⁶ is H; lower alkyl; lower alkenyl; aryl-lower alkyl; (CH₂),OR²²; (CH₂),SR²²; (CH₂),NR³³R³⁴; (CH₂),OCONR³³R⁷⁵; (CH₂),NR²⁶CONR³³R⁸²; (CH₂)₀COOR⁷⁵; (CH₂)₀CONR⁵⁸R⁵⁹; (CH₂)₀PO(OR⁶⁰)₂; (CH₂)₀SO₂R⁶²: or -(CH₂)_eCOR⁶⁴:

R77-is-R87; or a heteroaryl group of one of the formulae

Amendment and Response dated February 16, 2010
Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 17

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 18

R78 is H: lower alkyl; aryl; or aryl lower alkyl;

 $R^{78} \text{ and } R^{82} \text{ taken together can form: } (CH_2)_{2\cdot 6} \div (CH_2)_2 O(CH_2)_2 \div (CH_2)_2 S(CH_2)_2 \div or$

(CH₂)₂NR⁵²(CH₂)₂-;

R79 is H; lower alkyl; aryl; or aryl lower alkyl; or

 R^{78} and R^{79} , taken together, can be $(CH_2)_2 \cdot 7 + (CH_2)_2 \circ (CH_2)_2 + or \cdot (CH_2)_2 \cdot R^{89} (CH_3)_2 + R^{80} \cdot E \cdot V_{core} \cdot Order of kvii:$

R81 is H: lower alkyl; or aryl lower alkyl;

R⁸² is H; lower alkyl; aryl; heteroaryl; or aryl-lower alkyl;

R33 and R52 taken together can form: (CH2)26; (CH2)2O(CH2)2; (CH2)2S(CH2)2; or

(CH₂)₂+

R83 is H; lower alkyl; aryl; or NR78R39;

 R^{M} -is—(CH₂)₀CONR²⁸R²⁹;—(CH₂)₀NR⁶⁰CONR²⁸R²⁰;—(CH₂)₀C₀H₄CONR²⁸R²⁰;-of (CH₂)₀C₀H₄NR⁶⁰CONR²⁸R²⁰;

R⁸⁵ is lower alkyl; or lower alkenyl;

 $R^{86}\cdot is - R^{74}; \underbrace{-\{(CH_2)_o \cdot X\}_i \cdot (CH_2)_o \cdot NR^{78}}_{} R^{29}; \underbrace{-\{(CH_2)_o \cdot X\}_i \cdot (CH_2)_o \cdot C(=NR^{89})NR^{78}}_{} R^{29}; X \cdot is = 0 \cdot ,$

NR²⁰ , S , OCOO , u is 1-3, t is 1-6, v is 1-3;

R. F. is phenyl, p. hydroxyphenyl, 2. naphthyl, 1. naphthyl, 1. chlorophenyl, 3. chlorophenyl, 2. ehlorophenyl, 3. f. dichlorophenyl, 4. fluorophenyl, 3. fluorophenyl, 2. fluorophenyl, p. benzyloxyphenyl, p. biphenyl or p. benzoylphenyl.

with the proviso that in said chains Z and Z^{\dagger} of n and , respectively, $n^{\prime}\alpha$ amino acid residues

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 19

- if n is 4 and n' is 6_7 the amino acid residues in positions 1 to 4 of the chain Z and in positions 1' to 6' of in chain Z^1 are:
 - P1: of type C or of type D or of type E or of type F, or the residue is Pro

or Arg;

- P2: of type E or of type F L-citrulline (Cit) or Arg;
- P3: of type F, or the residue is Pro Cys;
- P4: of type E Arg-NH₂;
- P1': of type C or of type D or of type E or of type F, or the residue is Gly Lys

or Arg;

- P2': of type D or of type C Tyr;
 - P3': of type F or the residue is Pro Cys;
- P4': of type D or of type C L-2-naphthylalanine (2-Nal);
- P5': of type E, or of type F or the residue is Pro Arg; and
- P6': of type E or of type F, or the residue is Pro Arg; or
- Cys at P3 and P3', taken together, can form a group of type H disulfide bridge;

and

- if n is 5 and n' is 7, the amino acid residues in positions 1 to 5 of in chain Z and in positions 1' to 7' of in chain Z' are:
 - P1: of type C or of type D or of type E or of type F, or the residue is Pro Tyr;
 - P2: of type E or of type F Arg;
 - P3: of type F, or the residue is Pro Cit;
 - P4: of type F Cys;

Page 20

- P5: of type E Arg or Arg-NH₂
- PI': of type C or of type D or of type E or of type F, or the residue is Pro Lys;
- P2': of type F Cit;
- P3': of type D or the residue is Pro Tyr;
- P4': of type E or of type F Cys;
- P5': of type D, or the residue is Pro 2-Nal. Trp, L-para-aminophenylalanine

(F(pNH₂)) or L-6-Cl-Tryptophan (W(6-Cl));

- P6': of type E or of type F, or the residue is Pro Arg; and
- P7': of type E or of type I, or the residue is Gly DArg, Arg, Ac-Arg, iPf-Arg N-

(2-aminocthyl)glycine ((EA)G), N-(3-aminopropyl)glycine ((PrA)G), N-(4-amino-n-butyl)glycine ((BA)G), N-(2-guanidinocthyl)glycine ((EGU)G), N-(3-guanidino-n-

propyl)glycine ((PrGU)G), or N-(4-guanidino-n-butyl)glycine ((BGU)G); or Cys at P4 and P4' can form a disulfide bridge

P2 and P2' and/or P4 and P4', taken together, can form a group of type H;

at P7' also D-isomers being possible,

and an enantiomer thereof and pharmaceutically acceptable salts thereof.

41-46. (Previously cancelled)

47-49. (Cancelled)

50. (Currently amended) Compounds The compound according to claim 48 $\underline{40}$, wherein the α -amino acid residues in positions 1 to 4 of the chain Z and the α -amino acid residues in positions 1' to 6' chain Z' are:

Tyr, or Arg; P1:

P2: Cit, or Arg;

P3: Cys;

> Arg-NH2; P4:

PI': Lys, orArg;

P2': Tyr;

P3': Cys;

2-Nal: P4':

P5': Arg; Arg; and P6':

Cys at P3 and P3' can form a disulfide bridge.

- (Currently amended) Compounds The compound according to claim 49 40, wherein the 51. α -amino acid residues in positions 1 to 5 of the chain Z and the α -amino acid residues in positions 1' to 7' chain Z1 are:
 - P1: Tvr:
 - P2: Arg:
 - Cit; P3:
 - P4: Cys;
 - Arg, or Arg-NH2; P5:
 - P1': Lys;
 - P2': Cit:
 - P3': Tyr;
 - P4': Cys;
 - 2-Nal, Trp, F(pNH2), or W(6-Cl); P5'-
 - P6': Arg;
 - DArg, Arg, Ac-Arg, iPr-Arg, (EA)G, (PrA)G, (BA)G, (EGU)G, (PrGU)G, P7`: or (BGU)G; and

Cys at P4 and P4' can form a disulfide bridge.

- 52. (Currently amended) A <u>The</u> compound of formula I according to claim 40, wherein the template is ^DPro-Pro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions I' to 7' chain Z¹ are:
 - P1: Tyr;
 - P2: Arg;
 - P3: Cit;
 - P4: Cys;
 - P5: Arg-NH₂;
 - P1': Lys;
 - P2': Cit;
 - P3': Tyr:
 - P4': Cys;
 - P5': 2-Nal;
 - P6': Arg; and
 - P7': Arg; and

Cys at P4' and P4 forming a disulfide bridge.

- 53. (Currently amended) A <u>The</u> compound of formula 1 according to claim 40, wherein the template is ^DPro-¹Pro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z¹ are:
 - P1: Tyr;
 - P2: Arg;
 - P3: Cit;
 - P4: Cys;
 - P5: Arg-NH₂;
 - P1': Lys;

Page 23

- P2': Cit;

P3': Tyr;

P4': Cys;

P5': 2-Nal;

P6': Arg; and

P7': Ac-Arg; and

Cys at P4' and P4 forming a disulfide bridge.

- 54. (Currently amended) A <u>The</u> compound of formula 1 according to claim 40, wherein the template is ^DPro-¹Pro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z¹ are:
 - P1: Tyr;
 - P2: Arg;
 - P3: Cit;
 - . P4: Cys;
 - P5: Arg-NH₂;
 - P1': Lys;
 - P2': Cit;
 - P3': Tyr;
 - P4': Cvs:
 - P5': 2-Nal
 - P6': Arg; and
 - P7': DArg; and

Cys at P4' and P4 forming a disulfide bridge.

55. (Currently amended) A <u>The</u> compound of formula 1 according to claim 40, wherein the template is ^DPro-¹Pro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z¹ are:

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009 Docket No.: 753-54 PCT/US

Page 24

- P1: Tyr;
 - P2: Arg;
- P3: Cit:
- P4 · Cvs:
- P5: Arg-NH2;
- PI': Lys;
- P2': Cit:
- P3': Tyr;
- P4': Cys;
- P5': Phe(pNH2);
- Arg; and P6':
- P7': Arg; and

Cys at P4' and P4 forming a disulfide bridge.

- (Currently amended) A The compound of formula I according to claim 40, wherein the 56. template is ^DPro-^LPro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z^1 are:
 - P1: Tyr;
 - P2: Arg;
 - P3: Cit:
 - P4: Cys;
 - Arg-NH2; P5.
 - P1': Lys;
 - P2': Cit:
 - P3': Tvr: P4':
 - Cys; 2-Nal:
 - P5':
 - Arg; and P6':

Page 25

- P7': (PrA)G; and

Cys at P4' and P4 forming a disulfide bridge.

- 57. (Currently amended) A <u>The</u> compound of formula I according to claim 40, wherein the template is ^DPro-^LPro, n is 5, n' is 7 and the amino acid residues in positions 1 to 5 of the chain Z and the amino acid residues in positions 1' to 7' chain Z¹ are:
 - P1: Tyr;
 - P2: Arg;
 - P3: Cit;
 - P4: Cys;
 - P5: Arg;
 - PI': Lys;
 - P2': Cit;
 - P3': Tyr;
 - P4': Cys;
 - . P5': 2-Nal;
 - P6': Arg; and
 - P7': Arg; and

Cys at P4' and P4 forming a disulfide bridge.

58. (Currently amended) Enantiomers of the compounds of formulae I as defined in claim 40.

59.-60. (Cancelled)

 (Previously presented) A pharmaceutical composition containing a compound according to claim 40 and a pharmaceutically inert carrier.

Amendment and Response dated February 16, 2010

Reply to Office Action of October 14, 2009

Docket No.: 753-54 PCT/US

Page 26

62. (Currently amended) Compositions A composition according to claim 61 in a form suitable for a mode of administration selected from the group consisting of oral, topical, transdermal, injection, buccal, transmucosal, pulmonary and inhalation.

- 63. (Currently amended) Compositions A composition according to claim 61 in a form selected from the group consisting of tablets, dragees, capsules, solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, suspensions, spray, nebuliser or suppositories.
- 64. (Currently amended) Compositions A composition according to claim 62 in a form selected from the group consisting of tablets, dragees, capsules, solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, suspensions, spray, nebuliser or suppositories.
- 65. (Currently amended) A method for treating and/or-preventing a disorder selected from the group-consisting of HIV infections, cancer and inflammatory disorders, the method comprising mediated by or resulting from CXCR4 activity which comprises:

administering to a subject in need thereof of such treatment an effective amount of a compound according to claim 40.

- (Currently amended) A process for the manufacture of compounds according to claim 40, which process comprises
- (a) coupling an appropriately functionalized solid support with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 4 of Z if n is 4 or in position 5 of Z if n is 5—any functional group which may be present in said N protected amino acid derivative being likewise appropriately protected;
- (b) removing the N-protecting group from the product thus obtained;
- (c) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in Z of the desired end-product is one position nearer the N-terminal amino

acid residue, any functional group which may be present in said N protected amino acid derivative being likewise appropriately protected;

- (d) removing the N-protecting group from the product thus obtained;
- (e) repeating steps (c) and (d) until the N-terminal amino acid residue of Z has been introduced;
- (f) coupling the product thus obtained with a compound of the general formula



is as defined in claim 40 and X is an N-protecting group; or, alternatively,

(fa) coupling the product obtained in step (e) with an appropriately N-protected derivative of an amino acid of the general formula

wherein B-and-A are as defined in claim 40 ^LPro or ^DPro, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected:

- (fb) removing the N-protecting group from the product thus obtained; and
- (fc) coupling the product thus obtained with an appropriately N-protected derivative of an amino acid of the above general formula IV and, respectively, III Pro and, respectively, LPro, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

- (g) removing the N-protecting group from the product obtained in step (f) or (fc);
- (h) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 1 of Z¹, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- removing the N-protecting group from the product thus obtained;
- (j) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position farther away from position 1 of Z^1 , any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (k) removing the N-protecting group from the product thus obtained;
- (I) repeating steps (j) and (k) until all amino acid residues of Z¹ have been introduced;
- if desired, selectively deprotecting one or several protected functional group(s) present in the molecule and appropriately substituting the reactive group(s) thus liberated;
- (n) if desired, forming one or two interstrand linkage(s) between side-chains of appropriate amino acid residues at opposite positions of the β -strand region;
- (o) detaching the product thus obtained from the solid support and removing any protecting groups present on functional groups of any members of the chain of amino acid residues and, if desired, any protecting group(s) which may in addition be present in the molecule; and
- (p) if desired, converting the product thus obtained into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula 1 or into a different, pharmaceutically acceptable, salt.
- 67. (Currently amended) A process according to claim 66, but wherein an amino acid residue of type I a residue of glycine having the amino group substituted by a chain having a polar-cationic residue is introduced by coupling with a leaving group-containing acetylating acylating agent, followed by nucleophilic displacement with an amine of the formula H₂NR⁸⁶ having the amino group substituted by a chain having a polar-cationic residue which, if necessary, is appropriately protected.

Page 29

68. (Currently amended) A process according to claim 67 wherein the leaving group in said leaving group-containing aeetylating acylating agent is bromo, chloro or iodo acetic acid.

- 69. (Currently amended) A modification of the process according to claim 66 for the manufacture of compounds according to claim 56 58 in which enantiomers of all chiral starting materials are used.
- 70. (Currently amended) A modification of the process according to claim 67 for the manufacture of compounds according to claim \$6.58 in which enantiomers of all chiral starting materials are used.